Rankings
▼
Calendar
AMLX
Amylyx Pharmaceuticals, Inc.
$1B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$71M
Gross Profit
$66M
92.6% margin
Operating Income
-$2M
-2.9% margin
Net Income
$2M
2.2% margin
EPS (Diluted)
$0.02
QoQ Revenue Growth
+226.4%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$408M
Total Liabilities
$55M
Stockholders' Equity
$353M
Cash & Equivalents
$115M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$71M
$0
—
Gross Profit
$66M
$0
—
Operating Income
-$2M
-$48M
+95.7%
Net Income
$2M
-$48M
+103.3%
← FY 2023
All Quarters
Q2 2023 →
AMLX Q1 2023 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena